Amgen Earnings: Here’s Why Shares are Down Now

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Amgen Inc. (NASDAQ:AMGN) delivered a profit and beat Wall Street’s expectations, BUT came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 3.87%.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Amgen Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased 21.74% to $1.96 in the quarter versus EPS of $1.61 in the year-earlier quarter.

Revenue: Rose 4.69% to $4.24 billion from the year-earlier quarter.

Actual vs. Wall St. Expectations: Amgen Inc. reported adjusted EPS income of $1.96 per share. By that measure, the company beat the mean analyst estimate of $1.84. It missed the average revenue estimate of $4.37 billion.

Quoting Management: “We are on track to deliver our full-year growth objectives,” said Robert A. Bradway, chairman and chief executive officer at Amgen. “In addition, our key pipeline projects are progressing well and we are looking forward to clinical results from ongoing trials.”

Key Stats (on next page)…

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business